These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9471948)
1. Costs of amphotericin B lipid complex for kala-azar. Basnyat B Ann Intern Med; 1998 Feb; 128(4):326. PubMed ID: 9471948 [No Abstract] [Full Text] [Related]
2. A single high dose treatment of kala-azar with Ambisome (amphotericin B lipid complex): a pilot study. Thakur CP Int J Antimicrob Agents; 2001 Jan; 17(1):67-70. PubMed ID: 11137652 [TBL] [Abstract][Full Text] [Related]
4. Drug donated for treatment of visceral leishmaniasis. Burki T Lancet Infect Dis; 2012 Feb; 12(2):106-7. PubMed ID: 22389914 [No Abstract] [Full Text] [Related]
5. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Murray HW Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193 [TBL] [Abstract][Full Text] [Related]
6. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India. Murray HW Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475 [No Abstract] [Full Text] [Related]
7. Comment on: Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. de Górgolas M Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):1054; author reply 1054-5. PubMed ID: 17651771 [No Abstract] [Full Text] [Related]
8. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]. Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391 [TBL] [Abstract][Full Text] [Related]
9. [A case of antimony resistant kala-azar cured with amphotericin B]. Chen SB; Yang CM; Zhang CJ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767 [No Abstract] [Full Text] [Related]
10. India makes good progress in combating kala-azar. Cousins S Lancet; 2015 May; 385(9979):1716. PubMed ID: 25943925 [No Abstract] [Full Text] [Related]
11. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Thakur CP; Kumar A; Mitra G; Thakur S; Sinha PK; Das P; Bhattacharya SK; Sinha A Indian J Med Res; 2008 Jul; 128(1):38-44. PubMed ID: 18820357 [TBL] [Abstract][Full Text] [Related]
12. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis. Sundar S; Gupta LB; Rastogi V; Agrawal G; Murray HW Trans R Soc Trop Med Hyg; 2000; 94(2):200-4. PubMed ID: 10897369 [TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
14. Amphotericin B--fat emulsion in treatment of visceral leishmaniasis--a cost effective substitute for liposomal amphotericin B. Singh GP; Saxena RK; Priyadarshy V J Indian Med Assoc; 2010 Jan; 108(1):27-8. PubMed ID: 20839576 [TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis (kala-azar) in bone marrow aspirate. Economopoulos T; Giannopoulos G; Raptis S Eur J Haematol; 2002 Jun; 68(6):400. PubMed ID: 12225401 [No Abstract] [Full Text] [Related]
16. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Sundar S; Goyal AK; More DK; Singh MK; Murray HW Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533 [TBL] [Abstract][Full Text] [Related]